ABCELLERA BIOLOGICS (8QQ) — Cash Flow Reinvestment Rate

Latest as of December 2022: 1.24x

ABCELLERA BIOLOGICS (8QQ) has a Cash Flow Reinvestment Rate of 1.24x as of December 2022, reinvesting €343.38 Million (capex €72.66 Million plus investments €-270.72 Million) from operating cash flow of €277.36 Million. Check 8QQ cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

1.24x
(Capex + Investments) / Operating CF

Total Reinvested

€343.38 Million
Capex + Investments

Operating Cash Flow

€277.36 Million
EUR

Capital Expenditures

€72.66 Million
EUR

ABCELLERA BIOLOGICS Cash Flow Reinvestment Rate (2021–2022)

Historical reinvestment intensity for ABCELLERA BIOLOGICS across 2 annual periods. Explore long-term investment intensity of ABCELLERA BIOLOGICS to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for ABCELLERA BIOLOGICS (2021–2022)

Year-by-year capital reinvestment analysis for ABCELLERA BIOLOGICS. For live market cap and broader valuation context, see market cap of ABCELLERA BIOLOGICS.

Year Reinvestment Rate Total Reinvested (EUR) Operating CF Capex YoY Change
2022 1.24x €343.38 Million €277.36 Million €72.66 Million ▼ -6.3%
2021 1.32x €323.09 Million €244.58 Million €58.45 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow